KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
This guideline cites 5 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2026
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. Kidney Int. 2026;109(1S):S1–S99.doi 10.1016/j.kint.2025.06.006
Published in January 2026, this guideline finally replaces the 2012 anaemia document. Two things have changed in the interval: intravenous iron has been rehabilitated — proactive, higher-dose iron in haemodialysis is now the default rather than a reactive top-up — and a new drug class, the HIF prolyl-hydroxylase inhibitors, has arrived as an oral alternative to erythropoiesis-stimulating agents. The haemoglobin ceiling that the ESA trials established remains: correcting towards normal haemoglobin causes harm. The register's trials behind each of these positions are grouped below.
ESA therapy & haemoglobin targets3
- 2009TREAT CoreNephrology · Dialysis · Anaemia managementIn 4,038 patients with type 2 diabetes, CKD and anaemia, darbepoetin alfa did not reduce death or cardiovascular events and doubled the risk of stroke compared with placebo.HR 1.05Read →
- 2006CHOIRNephrology · Dialysis · Anaemia managementIn 1,432 patients with CKD and anaemia, targeting a higher haemoglobin with epoetin increased cardiovascular events compared with a lower haemoglobin target.HR 1.3495% CI 1.03-1.74Read →
- 2006CREATENephrology · Dialysis · Anaemia managementIn 603 patients with CKD and anaemia, complete correction of haemoglobin did not reduce cardiovascular events compared with partial correction.HR 0.7895% CI 0.53-1.14Read →
Iron therapy1
- 2019PIVOTALNephrology · Dialysis · Iron therapyIn 2,141 incident haemodialysis patients, proactive high-dose intravenous iron reduced death and cardiovascular events compared with a reactive low-dose regimen.HR 0.8595% CI 0.73-1.00Read →
HIF prolyl-hydroxylase inhibitors1
- 2021ASCEND-DNephrology · Dialysis · HIF-PHI anaemiaIn 2,964 dialysis patients with anaemia, the oral HIF prolyl-hydroxylase inhibitor daprodustat was non-inferior for haemoglobin and cardiovascular safety compared with erythropoiesis-stimulating agents.HR 0.9395% CI 0.81-1.07Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 1998Normal Hematocrit Trial
Normalising haematocrit with epoetin in haemodialysis increased death and myocardial infarction.
- 2021ASCEND-ND
Daprodustat in non-dialysis CKD — cardiovascular non-inferiority to darbepoetin.
- 2021INNO2VATE
Vadadustat in dialysis-dependent CKD: non-inferior for cardiovascular safety.
- 2021PRO2TECT
Vadadustat in non-dialysis CKD failed the cardiovascular non-inferiority margin.
- 2014FIND-CKD
Ferric carboxymaltose targeting higher ferritin delayed the need for other anaemia therapy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.